The idea that evidence can 'create' an equivalence of sensitivity raises crucial regulatory mandate questions for us, especially in the context of the ASIC. Our jurisdiction requires us to consider whether this 'creation' is a genuine innovation or simply the formalization of a pre-existing relationship. If the equivalence is conditional on very specific market assumptions, its applicability is limited, as in the case of shocks to commodity markets. A risk model that depends on a non-robust equivalence under market stress conditions, such as disruptions to global supply chains, would not be permitted.